Biological
Rilimogene glafolivec clinical trials
Also written PROSTVAC-F.
- studies test it
- 10
- open now
- 0
- in phase 3
- 1
- first study started
- 2003
How studies write it
Studies that test it under each name
Development codes
Studies by the year they started
10 studies that test it; most in 2003 (1)
| Year | Studies |
|---|---|
| 2003 | 1 |
| 2006 | 1 |
| 2007 | 1 |
| 2010 | 1 |
| 2011 | 1 |
| 2013 | 1 |
| 2014 | 1 |
| 2015 | 1 |
| 2016 | 1 |
| 2018 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 2
- Phase 2
- 8
- Phase 3
- 1
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 1 · Other 9
National Cancer Institute (NCI) (8) · Washington University School of Medicine (1) · Bavarian Nordic (1)
Often tested with
Tested in the same studies.
Rilimogene galvacirepvec (7) · Tricom (4) · Docetaxel (1) · Nivolumab (1) · Ipilimumab (1) · Vaccines, DNA (1) · Granulocyte-Macrophage Colony-Stimulating Factor (1) · rV-Tricom (1)
Studies
Open first, then newest update. How each study uses rilimogene glafolivec is read from its arms, and is right about nine times in ten.
Testing it · 10
- Docetaxel and PROSTVAC for Metastatic Castration-Sensitive Prostate CancerCompletedPhase 2National Cancer Institute (NCI)NCT02649855Written as PROSTVAC-F
- Prostvac in Patients With Biochemically Recurrent Prostate CancerCompletedPhase 2National Cancer Institute (NCI)NCT02649439Written as PROSTVAC-F
- Neoantigen DNA Vaccine in Combination With Nivolumab/Ipilimumab and PROSTVAC in Metastatic Hormone-Sensitive Prostate CancerCompletedPhase 1Washington University School of MedicineNCT03532217Written as PROSTVAC-F
- Enzalutamide in Combination With PSA-TRICOM in Patients With Non-Metastatic Castration Sensitive Prostate CancerCompletedPhase 2National Cancer Institute (NCI)NCT01875250Written as PROSTVAC-F (Fowlpox)/TRICOM
- A Randomized, Double-blind, Phase 3 Efficacy Trial of PROSTVAC-V/F +/- GM-CSF in Men With Asymptomatic or Minimally Symptomatic Metastatic Castrate-Resistant Prostate CancerCompletedPhase 3Bavarian NordicNCT01322490Written as PROSTVAC-F
- Vaccine Therapy With PROSTVAC/TRICOM and Flutamide Versus Flutamide Alone to Treat Prostate CancerCompletedPhase 2National Cancer Institute (NCI)NCT00450463Written as PROSTVAC-F/ TRICOM
- Vaccine Plus Booster Shots in Men With Prostate Cancer Undergoing Treatment With Radical ProstatectomyCompletedPhase 2National Cancer Institute (NCI)NCT02153918Written as PROSTVAC-F/TRICOM
- Sequential Vaccinations in Prostate Cancer PatientsCompletedPhase 1/2National Cancer Institute (NCI)NCT00060528Written as Recombinant Fowlpox-PSA (L155)-TRICOM (PROSTVAC-F/TRICOM)
- Docetaxel and Prednisone With or Without Vaccine Therapy in Treating Patients With Metastatic Hormone-Resistant Prostate CancerTerminatedPhase 2National Cancer Institute (NCI)NCT01145508Written as Recombinant Fowlpox-PSA(L155)/TRICOM Vaccine
- A Phase II Study of PROSTVAC-V (Vaccinia)/TRICOM and PROSTVAC-F (Fowlpox)/TRICOM With GM-CSF in Patients With PSA Progression After Local Therapy for Prostate CancerCompletedPhase 2National Cancer Institute (NCI)NCT00108732Written as Recombinant Fowlpox-PSA(L155)/TRICOM Vaccine
Given in every arm · 1 — rilimogene glafolivec is usual care beside what is tested
Codes
What other systems call rilimogene glafolivec · ClinicalTrials.gg INT015509
- UNII (FDA) 7PLH7RM47TRILIMOGENE GLAFOLIVECOne source FDA
- NCI Thesaurus C29560Rilimogene GlafolivecOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | 7PLH7RM47T | RILIMOGENE GLAFOLIVEC | One source FDA |
| NCI Thesaurus | C29560 | Rilimogene Glafolivec | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.